Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes

被引:30
作者
de Santiago, Ines [1 ]
Yau, Christopher [2 ]
Heij, Lara [3 ,4 ]
Middleton, Mark R. [5 ,6 ]
Markowetz, Florian [1 ]
Grabsch, Heike, I [3 ,7 ]
Dustin, Michael L. [8 ,9 ]
Sivakumar, Shivan [5 ,8 ]
机构
[1] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England
[2] Univ Birmingham, Ctr Computat Biol, Inst Canc & Genom Sci, Birmingham, W Midlands, England
[3] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Pathol, Med Ctr, Maastricht, Netherlands
[4] Univ Hosp RWTH Aachen, Dept Surg & Transplantat, Aachen, Germany
[5] Univ Oxford, Dept Oncol, Oxford, England
[6] Oxford Univ Hosp NHS Fdn Trust, OXford NIHR Biomed Res Ctr, Oxford, England
[7] Univ Leeds, Leeds Inst Med Res St Jamess, Div Pathol & Data Analyt, Leeds, W Yorkshire, England
[8] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England
[9] NYU, Sch Med, Dept Pathol, New York, NY USA
基金
英国医学研究理事会; 英国惠康基金;
关键词
pancreatic cancer; tumour microenvironment; T cells; adaptive immunity; innate immunity; subtypes; MUTATIONAL PROCESSES; METASTATIC MELANOMA; MOLECULAR SUBTYPES; ANALYSES REVEAL; CLASS DISCOVERY; PD-1; BLOCKADE; T-CELLS; TUMOR; SURVIVAL; INFILTRATION;
D O I
10.1002/ijc.32186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of the highest mortality rates of any cancer type with a 5-year survival rate of <5%. Recent studies of PDAC have provided several transcriptomic classifications based on separate analyses of individual patient cohorts. There is a need to provide a unified transcriptomic PDAC classification driven by therapeutically relevant biologic rationale to inform future treatment strategies. Here, we used an integrative meta-analysis of 353 patients from four different studies to derive a PDAC classification based on immunologic parameters. This consensus clustering approach indicated transcriptomic signatures based on immune infiltrate classified as adaptive, innate and immune-exclusion subtypes. This reveals the existence of microenvironmental interpatient heterogeneity within PDAC and could serve to drive novel therapeutic strategies in PDAC including immune modulation approaches to treating this disease.
引用
收藏
页码:1125 / 1137
页数:13
相关论文
共 50 条
  • [21] Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
    Bao, Quoc Riccardo
    Ventin, Marco
    Dell'Atti, Lorenzo
    Tripepi, Marzia
    Frigerio, Isabella
    Butturini, Giovanni
    Crimi, Filippo
    Scarpa, Marco
    Pucciarelli, Salvatore
    Ferrone, Cristina R.
    Spolverato, Gaya
    PANCREATOLOGY, 2024, 24 (07) : 1107 - 1114
  • [22] The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis
    Schorn, Stephan
    Demir, Ihsan Ekin
    Reyes, Carmen Mota
    Saricaoglu, Cemil
    Samm, Nicole
    Schirren, Rebekka
    Tieftrunk, Elke
    Hartmann, Daniel
    Friess, Helmut
    Ceyhan, Guralp Onur
    CANCER TREATMENT REVIEWS, 2017, 55 : 96 - 106
  • [23] Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance
    Ma, Ming-Zhe
    Kong, Xiang
    Weng, Ming-Zhe
    Cheng, Kun
    Gong, Wei
    Quan, Zhi-Wei
    Peng, Cheng-Hong
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2013, 32
  • [24] Intraductal papillary mucinous carcinoma versus pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
    Aronsson, Linus
    Bengtsson, Axel
    Toren, William
    Andersson, Roland
    Ansari, Daniel
    INTERNATIONAL JOURNAL OF SURGERY, 2019, 71 : 91 - 99
  • [25] A protein-based machine learning approach to the identification of inflammatory subtypes in pancreatic ductal adenocarcinoma
    Herremans, Kelly M.
    Underwood, Patrick W.
    Riner, Andrea N.
    Neal, Daniel W.
    Tushoski-Aleman, Gerik W.
    Forsmark, Christopher E.
    Nassour, Ibrahim
    Han, Song
    Hughes, Steven J.
    PANCREATOLOGY, 2023, 23 (06) : 615 - 621
  • [26] Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
    van Hilst, Jony
    Korrel, Maarten
    de Rooij, Thijs
    Lof, Sanne
    Busch, Olivier R.
    Koerkamp, Bas Groot
    Kooby, David A.
    van Dieren, Susan
    Abu Hilal, Mo
    Besselink, Marc G.
    EJSO, 2019, 45 (05): : 719 - 727
  • [27] Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
    Barrett, Michael T.
    Deiotte, Ray
    Lenkiewicz, Elizabeth
    Malasi, Smriti
    Holley, Tara
    Evers, Lisa
    Posner, Richard G.
    Jones, Timothy
    Han, Haiyong
    Sausen, Mark
    Velculescu, Victor E.
    Drebin, Jeffrey
    O'Dwyer, Peter
    Jameson, Gayle
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    BRITISH JOURNAL OF CANCER, 2017, 117 (04) : 572 - 582
  • [28] Genetics and biology of pancreatic ductal adenocarcinoma
    Ying, Haoqiang
    Kimmelman, Alec C.
    Bardeesy, Nabeel
    Kalluri, Raghu
    Maitra, Anirban
    Depinho, Ronald A.
    GENES & DEVELOPMENT, 2025, 39 (1-2) : 36 - 63
  • [29] Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
    Pervin, Jannat
    Asad, Mohammad
    Cao, Shaolong
    Jang, Gun Ho
    Feizi, Nikta
    Haibe-Kains, Benjamin
    Karasinska, Joanna M.
    O'Kane, Grainne M.
    Gallinger, Steven
    Schaeffer, David F.
    Renouf, Daniel J.
    Zogopoulos, George
    Bathe, Oliver F.
    FRONTIERS IN GENETICS, 2023, 14
  • [30] Deciphering fatty acid biosynthesis-driven molecular subtypes in pancreatic ductal adenocarcinoma with prognostic insights
    Xu, Junyi
    Liu, Mingzhu
    Xue, Jing
    Lu, Ping
    CELLULAR ONCOLOGY, 2024, 47 (04) : 1475 - 1491